Please ensure Javascript is enabled for purposes of website accessibility

2 Top Small-Cap Stocks to Buy in July

By Taylor Carmichael - Jul 8, 2021 at 6:39AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

OptimizeRx and Nano-X Imaging are two of my favorite small-caps right now. Here's why.

To make a lot of money in the stock market, it's key to focus on the small-cap section. What do I mean by "small-cap"? Historically, a small-cap stock was any company that had a market cap (share price multiplied by number of shares outstanding) of $2 billion or less. But these definitions were created back when a $100 billion company was considered huge. Now we have Apple and Microsoft valued at over $2 trillion.

So let's not get bogged down in definitions -- "small-cap" is relative. What we need to think about is market opportunity. How big can this small company get? The goal is to buy a $2 billion company, a $4 billion company, or a $6 billion company that has room to grow 10 times in value or more. Impossible? Nay, Fools. Happens all the time. What we need to do is find these small growth stocks, buy them, and hold them for years and years. (That last bit is probably the hardest!)

Person uses their laptop computer to have a virtual visit with their doctor.

Image source: Getty Images.

Here are two small-cap stocks that are in the sweet spot right now, using disruptive technology -- and the internet -- to make healthcare faster, better, and cheaper. I'm talking about OptimizeRx (OPRX -1.06%) and Nano-X Imaging (NNOX -0.43%)

The internet is fundamentally transforming healthcare

OptimizeRx stock was on fire last year. The stock started off 2020 at $10 a share, and by the end of the year it was changing hands at $30 a share. That's a nice 200% return for early investors. Now, six months later, the stock is approaching $60 a share. A six-bagger in 18 months. Sweet!

OPRX Chart

OPRX data by YCharts

What's going on with OptimizeRx? This tiny company -- its market cap is now $1 billion -- is changing how pharmaceutical companies and other healthcare players reach doctors. OptimizeRx is a miniature version of Teladoc Health. Instead of modifying how doctors meet with patients, OptimizeRx is redoing the pharmaceutical sales call.

Big Pharma spends $20 billion every year marketing drugs to physicians. Many doctors hate talking to sales reps -- 55% of healthcare players limit rep access. Yet, it's vital that doctors receive information about new studies and new drugs that are hitting the market.

OptimizeRx has figured out a way to use the internet to get doctors this vital information when they need it most -- while diagnosing a patient's illness. Doctors, on average, spend almost six hours a day using electronic health records (EHR) software to track patient health. OptimizeRx has deals in place with over 370 EHR software providers (it's a highly fragmented industry), allowing its internet platform to reach 60% of physicians. And OptimizeRx uses this access to target doctors with relevant pharmaceutical data during the actual clinical workflow.

While the shutdown certainly accelerated the move to virtual healthcare, in my opinion this trend is just getting started. I suspect the role of pharmaceutical sales reps will become more and more virtual as the internet makes information flow ever faster, better, and cheaper. I'm hopeful OptimizeRx shareholders will ride this trend to a 10-bagger in valuation over the next decade. 

Nano-X is on the verge of FDA clearance

Nano-X (pronounced "Nan-ox") is about to unleash its new X-ray device to the world. Last fall, naysayers were calling the company a fraud, saying there was no way its $10,000 X-ray device could actually work. Fast-forward several months, and Nano-X already has one clearance from the U.S. Food and Drug Administration (FDA) under its belt. It's expecting two more later this year.

Nano-X's imaging device will be radically cheaper than the existing MRI (magnetic resonance imaging) and CAT (computed axial tomography) scanners in use today. Those devices cost hospitals over $1 million, and often up to $3 million, to install.

Doctor looks at a contact sheet of X-ray images.

Image source: Getty Images.

Nano-X's $10,000 device produces the same quality of X-ray images as those high-end machines. How, then, can the company manufacture its machine so cheaply? 

The company bought the rights to nano-tech that was developed by engineers at Sony for flat-screen televisions. Nano-X spent the next eight years transferring the MEMS (micro-electro-mechanical systems) involved in this tech into a new X-ray machine. The key breakthrough was a cold cathode technology that allows these images to be powered digitally, without all the heat (2,000 degrees Celsius/3,632 degrees Fahrenheit) that existing systems require.

The cost reductions are amazing. The massive legacy tubes cost X-ray manufacturers $150,000 to make. Nano-X's miniaturized tube runs about $100.

The FDA has already cleared the single-source device, validating the technology. A couple of weeks ago, Nano-X submitted its FDA application for its multi-source device -- the machine that will compete with MRI and CAT scanners. And then Nano-X will submit its third FDA application; this one is for its software platform, NANOX.cloud.

It's the last of these that will allow Nano-X to operate as a SaaS (software-as-a-service) provider, pulling in subscription revenue as doctors store and share X-rays online. The company envisions a price point of $40 per X-ray scan, and Nano-X will bring in $14 every time one of its devices is used.

NNOX Chart

NNOX data by YCharts

The stock has been incredibly volatile, running up on a massive short squeeze and then crashing back down to earth. But the upside remains incredible. I believe Nano-X will radically expand X-ray technology around the world, and X-ray use will become far more common. This is one small-cap that has a huge market opportunity ahead.

 

Teresa Kersten, an employee of LinkedIn, a Microsoft subsidiary, is a member of The Motley Fool’s board of directors. Taylor Carmichael owns shares of Apple, Nano-X Imaging Ltd., and OptimizeRx Corporation. The Motley Fool owns shares of and recommends Apple, Microsoft, and Teladoc Health. The Motley Fool recommends the following options: long March 2023 $120 calls on Apple and short March 2023 $130 calls on Apple. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

OptimizeRx Corporation Stock Quote
OptimizeRx Corporation
OPRX
$24.23 (-1.06%) $0.26
Microsoft Corporation Stock Quote
Microsoft Corporation
MSFT
$282.91 (-0.26%) $0.74
Apple Inc. Stock Quote
Apple Inc.
AAPL
$165.35 (-0.14%) $0.23
Sony Corporation Stock Quote
Sony Corporation
SONY
$86.32 (0.43%) $0.37
Teladoc Health, Inc. Stock Quote
Teladoc Health, Inc.
TDOC
$37.48 (0.05%) $0.02
Nano-X Imaging Ltd. Stock Quote
Nano-X Imaging Ltd.
NNOX
$14.05 (-0.43%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.